第1章 グローバル心血管遺伝子検査市場 エグゼクティブサマリー
1.1. グローバル心血管遺伝子検査市場規模および予測（2022年～2032年）
1.2. 地域別概要
1.3. 分野別概要
1.3.1. 疾患別
1.3.2. 技術別
1.3.3. 検査タイプ別
1.3.4. 用途別
1.4. 主要トレンド
1.5. 不況の影響
1.6. アナリストの推奨および結論

第2章 世界の心血管遺伝子検査市場の定義と調査の前提条件
2.1. 調査目的
2.2. 市場の定義
2.3. 調査の前提条件
2.3.1. 対象および除外
2.3.2. 制限
2.3.3. 供給サイド分析
2.3.3.1. 可用性
2.3.3.2. インフラ
2.3.3.3. 規制環境
2.3.3.4. 市場競争
2.3.3.5. 経済的実現可能性（消費者視点
2.3.4. 需要側分析
2.3.4.1. 規制枠組み
2.3.4.2. 技術的進歩
2.3.4.3. 環境への配慮
2.3.4.4. 消費者意識と受容
2.4. 推定方法
2.5. 調査対象年
2.6. 通貨換算レート

第3章 世界の心血管遺伝子検査市場のダイナミクス
3.1. 市場推進要因
3.1.1. 心血管系疾患の発生率上昇
3.1.2. 低侵襲技術の利用増加
3.2. 市場の課題
3.2.1. データ管理と解釈
3.2.2. 患者と医療提供者の受容
3.3. 市場機会
3.3.1. 医療へのアクセスと手頃な価格の改善
3.3.2. 健康増進と予防医療への取り組み

第4章 世界の心血管遺伝子検査市場の業界分析
4.1. ポーターの5つの力モデル
4.1.1. 供給業者の交渉力
4.1.2. 購入業者の交渉力
4.1.3. 新規参入の脅威
4.1.4. 代替品の脅威
4.1.5. 競争上の競合
4.2. PESTEL分析
4.2.1. 政治
4.2.2. 経済
4.2.3. 社会
4.2.4. 技術
4.2.5. 環境
4.2.6. 法律
4.3. 最大の投資機会
4.4. 最大の成功戦略
4.5. 破壊的トレンド
4.6. 業界専門家による見解
4.7. アナリストの推奨事項と結論

第5章 疾患別世界の心血管遺伝子検査市場規模および予測（2022年～2032年）
5.1. セグメントダッシュボード
5.2. 世界の心血管遺伝子検査市場：疾患別収益動向分析、2022年および2032年（10億米ドル
5.2.1. 遺伝性心筋症
5.2.2. 肥大型心筋症（HCM）
5.2.3. 拡張型心筋症（DCM）
5.2.4. 不整脈
5.2.5. 大動脈疾患
5.2.6. その他

第6章 グローバル心血管遺伝子検査市場規模・予測（2022年～2032年）技術別
6.1. セグメントダッシュボード
6.2. グローバル心血管遺伝子検査市場：技術別収益動向分析（2022年および2032年）（10億米ドル
6.2.1. 細胞遺伝学的検査
6.2.2. 生化学的検査
6.2.3. 分子検査

第7章 遺伝子検査市場規模・予測（2022年～2032年） 検査タイプ別
7.1. セグメントダッシュボード
7.2. 遺伝子検査市場：検査タイプ別収益動向分析（2022年～2032年）（単位：10億米ドル）
7.2.1. 予測検査
7.2.2. 保因者検査
7.2.3. 出生前および新生児検査
7.2.4. 診断検査
7.2.5. 薬理ゲノム検査
7.2.6. その他

第8章 グローバル心血管遺伝子検査市場規模および予測（2022年～2032年）用途別
8.1. セグメントダッシュボード
8.2. 世界の心血管遺伝子検査市場：用途別収益動向分析、2022年および2032年（10億米ドル
8.2.1. 染色体分析
8.2.2. 遺伝性疾患診断
8.2.3. 心血管疾患診断
8.2.4. その他

第9章 地域別世界の心血管遺伝子検査市場規模および予測（2022年～2032年）
9.1. 北米の心血管遺伝子検査市場
9.1.1. 米国の心血管遺伝子検査市場
9.1.1.1. 疾患別市場規模および予測、2022年～2032年
9.1.1.2. 技術別内訳の規模と予測、2022年～2032年
9.1.1.3. 検査タイプ別内訳の規模と予測、2022年～2032年
9.1.1.4. 用途別内訳の規模と予測、2022年～2032年
9.1.2. カナダの心血管遺伝子検査市場
9.2. 欧州の心血管遺伝子検査市場
9.2.1. 英国の心血管遺伝子検査市場
9.2.2. ドイツの心血管遺伝子検査市場
9.2.3. フランスの心血管遺伝子検査市場
9.2.4. スペインの心血管遺伝子検査市場
9.2.5. イタリアの心血管遺伝子検査市場
9.2.6. その他の欧州の心血管遺伝子検査市場
9.3. アジア太平洋地域の心血管遺伝子検査市場
9.3.1. 中国の心血管遺伝子検査市場
9.3.2. インドの心血管遺伝子検査市場
9.3.3. 日本の心血管遺伝子検査市場
9.3.4. オーストラリアの心血管遺伝子検査市場
9.3.5. 韓国の心血管遺伝子検査市場
9.3.6. アジア太平洋地域（日本を除く）の心血管遺伝子検査市場
9.4. ラテンアメリカの心血管遺伝子検査市場
9.4.1. ブラジルの心血管遺伝子検査市場
9.4.2. メキシコの心血管遺伝子検査市場
9.4.3. その他の中南米の心血管遺伝子検査市場
9.5. 中東およびアフリカの心血管遺伝子検査市場
9.5.1. サウジアラビアの心血管遺伝子検査市場
9.5.2. 南アフリカの心血管遺伝子検査市場
9.5.3. その他の中東およびアフリカの心血管遺伝子検査市場

第10章 競合情報
10.1. 主要企業のSWOT分析
10.1.1. 企業1
10.1.2. 企業2
10.1.3. 企業3
10.2. トップ市場戦略
10.3. 企業プロフィール
10.3.1. Bio-Rad Laboratories Inc.
10.3.1.1. 重要情報
10.3.1.2. 概要
10.3.1.3. 財務（データ入手可能時
10.3.1.4. 製品概要
10.3.1.5. 市場戦略
10.3.2. Danaher
10.3.3. Thermo Fisher Scientific, Inc.
10.3.4. Daan Gene Co., Ltd.
10.3.5. F. Hoffmann-La Roche, Ltd.
10.3.6. Genentech, Inc.
10.3.7. Genomictree, Inc.
10.3.8. HTG Molecular Diagnostics, Inc.
10.3.9. Illumina, Inc.
10.3.10. Integragen
10.3.11. Laboratory Corporation of America Holdings
10.3.12. Luminex Corporation
10.3.13. Molecular MD Corp.
10.3.14. Myriad Genetics, Inc.
10.3.15. Natera, Inc.

第11章 研究プロセス
11.1. 研究プロセス
11.1.1. データマイニング
11.1.2. 分析
11.1.3. 市場推定
11.1.4. 検証
11.1.5. 公開
11.2. 研究の属性

Global Cardiovascular Genetic Testing Market is valued at approximately USD 9.07 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.2% over the forecast period 2024-2032.

Cardiovascular genetic testing is an increasingly vital tool for assessing an individual’s genetic risk for a spectrum of cardiovascular diseases, including coronary artery disease, hypertension, cardiomyopathies, and other related disorders. Given the rapidly growing prevalence of cardiovascular conditions globally, early detection through genetic testing facilitates the implementation of targeted preventive measures, thereby reducing the morbidity and mortality associated with these diseases.

The rising incidence of cardiovascular diseases, particularly coronary artery disease (CAD), is a significant driver propelling the growth of the cardiovascular genetic testing market. With an estimated 18.6 million deaths attributed to cardiovascular diseases each year, the demand for early detection methods is intensifying. According to the World Health Organization (WHO), cardiovascular disease remains the leading cause of death worldwide, claiming approximately 17.9 million lives annually. Furthermore, projections indicate that by 2030, this number could exceed 23 million, underscoring the critical need for advanced diagnostic tools like genetic testing in cardiovascular care. Additionally, the growing adoption of minimally invasive techniques, including catheter-based interventions and robot-assisted surgeries, is enhancing the scope of cardiovascular care applications. These advancements offer numerous advantages such as faster recovery times, reduced complication risks, and shorter hospital stays, thereby boosting the demand for cardiovascular genetic testing.

The global market is also benefiting from increased wellness and preventive health initiatives. As preventive healthcare gains traction, there is a growing interest among individuals to understand their hereditary risk factors for cardiovascular diseases. Public health campaigns and educational initiatives are raising awareness about the importance of proactive healthcare, which is driving the demand for genetic testing. However, the market faces challenges, including the complexities of data management and interpretation, and the ethical and privacy concerns associated with the handling of sensitive genetic information. These factors could potentially hinder the market's growth.

The global cardiovascular genetic testing market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Rest of the World. North America dominates the market, with the U.S. leading the region due to a large patient population and strong demand for innovative therapies. Favorable reimbursement policies and the presence of key market players further bolster the market in this region. Meanwhile, the Asia-Pacific region is expected to witness significant growth due to rising awareness about cardiovascular diseases, expanding healthcare infrastructure, and increasing prevalence in densely populated countries like China and India. The region's market is also driven by the growing number of retail pharmacies and improving access to healthcare services.

Major market players included in this report are:
Bio-Rad Laboratories Inc. (U.S.)
Danaher
Thermo Fisher Scientific, Inc.
Daan Gene Co., Ltd.
F. Hoffmann-La Roche, Ltd.
Genentech, Inc.
Genomictree, Inc.
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Integragen
Laboratory Corporation of America Holdings
Luminex Corporation
Molecular MD Corp.
Myriad Genetics, Inc.
Natera, Inc.

The detailed segments and sub-segment of the market are explained below:
By Disease:
Inherited Cardiomyopathies
Hypertrophic Cardiomyopathy (HCM)
Dilated Cardiomyopathy (DCM)
Arrhythmia
Aortopathies
Others

By Technology:
Cytogenetic Testing
Biochemical Testing
Molecular Testing

By Testing Type:
Predictive Testing
Carrier Testing
Prenatal and Newborn Testing
Diagnostic Testing
Pharmacogenomic Testing
Others

By Application:
Chromosome Analysis
Genetic Disease Diagnosis
Cardiovascular Disease Diagnosis
Others
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Cardiovascular Genetic Testing Market Executive Summary
1.1. Global Cardiovascular Genetic Testing Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Disease
1.3.2. By Technology
1.3.3. By Testing Type
1.3.4. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Cardiovascular Genetic Testing Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Cardiovascular Genetic Testing Market Dynamics
3.1. Market Drivers
3.1.1. Rising Incidence of Cardiovascular Diseases
3.1.2. Increasing Utilization of Minimally Invasive Techniques
3.2. Market Challenges
3.2.1. Data Management and Interpretation
3.2.2. Patient and Provider Acceptance
3.3. Market Opportunities
3.3.1. Improved Healthcare Access and Affordability
3.3.2. Wellness and Preventive Health Initiatives

Chapter 4. Global Cardiovascular Genetic Testing Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Cardiovascular Genetic Testing Market Size & Forecasts by Disease (2022-2032)
5.1. Segment Dashboard
5.2. Global Cardiovascular Genetic Testing Market: Disease Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Inherited Cardiomyopathies
5.2.2. Hypertrophic Cardiomyopathy (HCM)
5.2.3. Dilated Cardiomyopathy (DCM)
5.2.4. Arrhythmia
5.2.5. Aortopathies
5.2.6. Others

Chapter 6. Global Cardiovascular Genetic Testing Market Size & Forecasts by Technology (2022-2032)
6.1. Segment Dashboard
6.2. Global Cardiovascular Genetic Testing Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Cytogenetic Testing
6.2.2. Biochemical Testing
6.2.3. Molecular Testing

Chapter 7. Global Cardiovascular Genetic Testing Market Size & Forecasts by Testing Type (2022-2032)
7.1. Segment Dashboard
7.2. Global Cardiovascular Genetic Testing Market: Testing Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Predictive Testing
7.2.2. Carrier Testing
7.2.3. Prenatal and Newborn Testing
7.2.4. Diagnostic Testing
7.2.5. Pharmacogenomic Testing
7.2.6. Others

Chapter 8. Global Cardiovascular Genetic Testing Market Size & Forecasts by Application (2022-2032)
8.1. Segment Dashboard
8.2. Global Cardiovascular Genetic Testing Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Chromosome Analysis
8.2.2. Genetic Disease Diagnosis
8.2.3. Cardiovascular Disease Diagnosis
8.2.4. Others

Chapter 9. Global Cardiovascular Genetic Testing Market Size & Forecasts by Region (2022-2032)
9.1. North America Cardiovascular Genetic Testing Market
9.1.1. U.S. Cardiovascular Genetic Testing Market
9.1.1.1. Disease Breakdown Size & Forecasts, 2022-2032
9.1.1.2. Technology Breakdown Size & Forecasts, 2022-2032
9.1.1.3. Testing Type Breakdown Size & Forecasts, 2022-2032
9.1.1.4. Application Breakdown Size & Forecasts, 2022-2032
9.1.2. Canada Cardiovascular Genetic Testing Market
9.2. Europe Cardiovascular Genetic Testing Market
9.2.1. U.K. Cardiovascular Genetic Testing Market
9.2.2. Germany Cardiovascular Genetic Testing Market
9.2.3. France Cardiovascular Genetic Testing Market
9.2.4. Spain Cardiovascular Genetic Testing Market
9.2.5. Italy Cardiovascular Genetic Testing Market
9.2.6. Rest of Europe Cardiovascular Genetic Testing Market
9.3. Asia-Pacific Cardiovascular Genetic Testing Market
9.3.1. China Cardiovascular Genetic Testing Market
9.3.2. India Cardiovascular Genetic Testing Market
9.3.3. Japan Cardiovascular Genetic Testing Market
9.3.4. Australia Cardiovascular Genetic Testing Market
9.3.5. South Korea Cardiovascular Genetic Testing Market
9.3.6. Rest of Asia Pacific Cardiovascular Genetic Testing Market
9.4. Latin America Cardiovascular Genetic Testing Market
9.4.1. Brazil Cardiovascular Genetic Testing Market
9.4.2. Mexico Cardiovascular Genetic Testing Market
9.4.3. Rest of Latin America Cardiovascular Genetic Testing Market
9.5. Middle East & Africa Cardiovascular Genetic Testing Market
9.5.1. Saudi Arabia Cardiovascular Genetic Testing Market
9.5.2. South Africa Cardiovascular Genetic Testing Market
9.5.3. Rest of Middle East & Africa Cardiovascular Genetic Testing Market

Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Company 1
10.1.2. Company 2
10.1.3. Company 3
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Bio-Rad Laboratories Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Danaher
10.3.3. Thermo Fisher Scientific, Inc.
10.3.4. Daan Gene Co., Ltd.
10.3.5. F. Hoffmann-La Roche, Ltd.
10.3.6. Genentech, Inc.
10.3.7. Genomictree, Inc.
10.3.8. HTG Molecular Diagnostics, Inc.
10.3.9. Illumina, Inc.
10.3.10. Integragen
10.3.11. Laboratory Corporation of America Holdings
10.3.12. Luminex Corporation
10.3.13. Molecular MD Corp.
10.3.14. Myriad Genetics, Inc.
10.3.15. Natera, Inc.

Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

❖ 世界の心血管遺伝子検査市場に関するよくある質問(FAQ) ❖

・心血管遺伝子検査の世界市場規模は？
→Bizwit Research & Consulting社は2023年の心血管遺伝子検査の世界市場規模を90.7億米ドルと推定しています。

・心血管遺伝子検査の世界市場予測は？
→Bizwit Research & Consulting社は2032年の心血管遺伝子検査の世界市場規模をXX米ドルと予測しています。

・心血管遺伝子検査市場の成長率は？
→Bizwit Research & Consulting社は心血管遺伝子検査の世界市場が2024年～2032年に年平均11.2%成長すると予測しています。

・世界の心血管遺伝子検査市場における主要企業は？
→Bizwit Research & Consulting社は「Bio-Rad Laboratories Inc. (U.S.)、Danaher、Thermo Fisher Scientific, Inc.、Daan Gene Co., Ltd.、F. Hoffmann-La Roche, Ltd.、Genentech, Inc.、Genomictree, Inc.、HTG Molecular Diagnostics, Inc.、Illumina, Inc.、Integragen、Laboratory Corporation of America Holdings、Luminex Corporation、Molecular MD Corp.、Myriad Genetics, Inc.、Natera, Inc.など ...」をグローバル心血管遺伝子検査市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。